Liraglutide: The Once-Daily GLP-1 That Pioneered Physician-Supervised Weight Loss
Liraglutide holds a significant place in the history of obesity medicine: it was the first GLP-1 receptor agonist to receive FDA approval specifically for chronic weight management in adults without diabetes (3mg daily, approved 2014). Before liraglutide, the idea that a weekly or daily injectable hormone analog could produce sustainable, clinically meaningful weight loss was unproven. Liraglutide proved it.
How Liraglutide Works
Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to endogenous human GLP-1. Its half-life of approximately 13 hours — achieved through albumin binding and structural modifications — makes it suitable for once-daily subcutaneous injection, compared to semaglutide's once-weekly dosing.
Its mechanisms are identical to other GLP-1 agonists: appetite suppression via hypothalamic GLP-1 receptors, delayed gastric emptying, glucose-dependent insulin secretion, glucagon suppression, and reward pathway modulation. The daily dosing requirement produces more consistent, though less peaked, plasma levels compared to weekly semaglutide.
SCALE Trial Results (FDA Approval Basis)
The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trial program was the pivotal study program that led to FDA approval for weight management:
SCALE Obesity and Prediabetes: (56 weeks, n=3,731): Liraglutide 3mg produced **8.4% mean body weight reduction** vs. 2.8% for placebo. 63.2% of liraglutide-treated patients achieved ≥5% weight loss (vs. 27.1% placebo). 33.1% achieved ≥10% weight loss.
SCALE Diabetes: (56 weeks, T2D population): 6.0% mean weight reduction with liraglutide 3mg vs. 2.0% with placebo.
SCALE Maintenance: Sustained weight loss demonstrated over 56 additional weeks in patients continuing liraglutide after initial weight loss.
Liraglutide vs. Semaglutide
Semaglutide at 2.4mg produces approximately 15% weight reduction vs. liraglutide's 8.4% at its highest dose. For patients who respond well to liraglutide or who prefer once-daily dosing over once-weekly injection, liraglutide remains a clinically appropriate choice. Daily dosing also allows more granular titration control.
Liraglutide is a prescription GLP-1 medication. Not everyone qualifies. A licensed provider determines eligibility and dosing based on individual medical history and weight management goals.
